No announcement yet.

COVID-19 variant 1.617 series including 1.617.2 Delta & 1.617.1 Kappa, and AY.1 mutation

This is a sticky topic.
  • Filter
  • Time
  • Show
Clear All
new posts

  • COVID-19 variant 1.617 series including 1.617.2 Delta & 1.617.1 Kappa, and AY.1 mutation

    Confirming the enhanced power of the virus, District COVID Special Officer and Principal of Andhra Medical College P.V. Sudhakar said,?We have observed that the new variant has shorter incubation period and the progress of the disease is much rapid. In the earlier cases, a patient affected with the virus would take at least a week to reach the hypoxia or dyspnea stage. But in the present context, patients are reaching the serious condition stage within three orfour days. And that is why there is heavy pressure on beds with oxygen orICU beds,? he said. Experts also point out that unlike during the first wave, a shorter exposure is enough to acquire the virus, which enables an infected person to infect fourto five persons, within a shorter contact span. ?Most essentially, none is spared, as we have observed that it is affecting the younger population in a big way, including those who are fitness freaks and have high immunity levels. It is also observed that cytokine storm is occurring faster, and some are responding to treatment and some are not,? said Dr. Sudhakar.

  • #2
    I copied a post from another thread to start this thread. So far there has been very little news/studies about the 1.6 variant series.

    Please see our India forum for more news. link

    UK government reports 400 cases of COVID-19 variant 1.617 that was first seen in India - April 27, 2021

    The CDC is reporting no cases in the US, but this is highly unlikely. link


    • Okieman
      Okieman commented
      Editing a comment
      We know that they are out there in the U.S. and Canada based upon media reports. What happens over the next couple of months is very important.

    • sharon sanders
      sharon sanders commented
      Editing a comment
      CDC just now posted these: CDC Update On SARS-CoV-2 Variant Classifications and Definitions - Adds 5 VOIs To List

  • #3
    Double mutant of coronavirus fast replacing dominant N440K variant in south India: Scientists

    By: PTI |
    May 4, 2021 9:32 PM

    The B.1.617 variant harbours 15 lineage defining mutations. B.1.617, initially termed as the double mutant, has three new spike protein mutations.

    The B.1.617 variant of the coronavirus, also known as the double mutant, is fast replacing the N440K variant in south India, scientists at the Centre for Cellular and Molecular Biology (CCMB) said on Tuesday.

    Former CCMB director Rakesh Mishra said the double mutant is now a dominant variant in Karnataka, Andhra Pradesh and now Telangana.

    After an exhaustive analysis of 5,000 variants earlier this year, the CCMB had found that N440K is spreading a lot more in the southern states compared to the other variants.

    But B.1.617 is fast replacing N440K, including in Kerala, Divya Tej Sowpati, a scientist with the CCMB, said.



    • #4
      CDC just posted these - 4 are the 1.6 series originating out of India....

      CDC Update On SARS-CoV-2 Variant Classifications and Definitions - Adds 5 VOIs To List


      • #5
        U.S. infectious disease expert died after being vaccinated with 2 shots of Pfizer vaccine in India
        May 05, 2021 13:01 Observer Network

        On May 3, Indian-American infectious disease expert Rajendra Kapila (Rajendra Kapila) died after contracting the new crown virus in India. Since he had completed two injections of Pfizer's new coronavirus vaccine before going to India, the incident has attracted attention from the outside world.

        According to a report on the website of the Hindustan Times on May 4, Dr. Kapila returned to India from the United States with his wife, Doctor of Microbiology, Deepti Saxena-Kapila at the end of March. Ghaziabad in Uttar Pradesh in order to take care of his elderly father-in-law.

        He was supposed to fly back to the United States in the second week of April, but contracted the new crown virus and was admitted to the Shanti Mukund Hospital in Delhi, where he died soon afterwards.

        Mrs. Capilla confirmed that Capilla had completed two injections of Pfizer?s new crown vaccine before departure.

        She told the Hindustan Times: "For the past year, we have been working in a new coronavirus laboratory in New Jersey. We can ensure a safe and uninfected environment at home, but the irony is that we have just arrived in India for two weeks. , My husband passed away here."

        Dr. Kapila is an Indian-American infectious disease expert who has engaged in a large number of tropical medicine, travel diseases and AIDS research during his lifetime. Kapila received a Bachelor of Medicine degree from the University of Delhi, India, and has been practicing in India for some time. After that, Kapila immigrated to the United States and entered the University of New Jersey Medical and Dental School in 1973.

        Kapila participated in the founding of the New Jersey Infectious Disease Society, and won the Distinguished Teaching Award from the University of New Jersey Medical and Dental Medicine. After most of the school was merged into Rogers University, Capilla became a professor at the Rogers University School of Medicine. After the start of the new crown epidemic, Capilla also conducted a lot of research and gave a speech on the use of antibodies to treat new coronary pneumonia in June last year.

        Robert Schwartz, a member of the US Presidential Advisory Committee on AIDS, confirmed the death of Dr. Kapila on the morning of May 3, local time in the United States, and paid tribute to Kapila's family. Kapila and Robert Schwartz have been friends for many years and have co-published many papers.

        Schwartz said: "As a true giant in the field of infectious diseases, Dr. Kapila is recognized worldwide. He is highly regarded for his rich knowledge and extraordinary clinical experience in diagnosing and treating the most complex infectious diseases. . He is a veteran and advocates providing the best medical care for everyone. His wise and exemplary behavior will be remembered forever."

        It is not clear how Kapila was infected with the new coronavirus in India, and the Indian media did not say whether Ruihui's vaccine provided him with protection, nor whether he was infected with a variant of the new coronavirus.

        The epidemic situation in India is getting more and more severe, and the double variant of the new crown currently found in India is gradually becoming the "main spreading force." According to a CCTV news report on May 5, scientists at the local Indian Center for Cell and Molecular Biology said that in some southern Indian states, the new coronavirus mutant strain B.1.617, which was previously called a "double mutant virus" by the media, has become locally transmitted. The main variant strain.

        This mutant strain carries E484Q and L452R mutations, which may lead to immune escape and increased infectivity. In the southern Indian states of Karnataka, Andhra Pradesh and Telangana, B.1.617 is now dominating.

        Ruihui vaccine refers to the new crown vaccine BNT162b2, a new crown vaccine jointly developed by Pfizer and BioNTech. It is an mRNA vaccine with strong protection. The final data of the previous phase III clinical trial of the vaccine showed that the effectiveness of Ruihui vaccine was 95%, and the effective rate was more than 94% in adults over 65 years of age.

        In the May 4 financial report of Pfizer and BioNTech, as of May 3, the two companies have shipped approximately 430 million doses of vaccines to 91 countries and regions in the world.



        • #6

          An 81-year-old world-renowned infectious disease doctor has died due to Covid-19 in the capital. Dr Rajendra Kapila of Rutgers University passed away on April 28 in Karkardooma?s Shanti Mukand Hospital after having contracted the disease earlier in the month, said an official from the hospital. Dr Kapila worked in Rutgers University for the last 50 years and specialised in infectious diseases.

          ?For one-half century, Dr Kapila served as a foundational pillar of New Jersey Medical School, the Martland Hospital and the University Hospital, where he provided care to tens of thousands of patients and trained numerous generations of medical students, residents and fellows. A genuine giant in the field of infectious diseases, Dr Kapila was recognised worldwide and sought out for his legendary knowledge and extraordinary clinical acumen in diagnosing complex diseases. He made invaluable contributions about AIDS (1983). He will be deeply missed,? said Dr Marc Klapholz, Chair, Department of Medicine Rutgers University.


          • #7
            This article has detailed data about the ages and pre-existing conditions, if any, of those who died. Most had only the first dose, but nobody had been dying after the first dose before so they were getting some protection.

            Google map and weather data.

            06 May 2021 | 06:52am IST 28 of those who died had received the vaccine

            Team Herald

            PANJIM: From April 23, Directorate of Health Services (DHS) began to add to their daily COVID mortality bulletins, information that contained details whether the deceased had taken a vaccine dose or not.

            A day prior to that on April 22, Goa Medical College (GMC) Dean Dr Shivanand Bandekar and Health Secretary Ravi Dhawan had stated that there had been no deaths of people who had taken a vaccine dose.

            However, from April 23 onwards, barring two days, the mortality bulletins have reported 28 deaths of people who had taken the vaccine doses...

            Ask Congress to Investigate COVID Origins and Government Response to Pandemic H.R. 834

            i love myself. the quietest. simplest. most powerful. revolution ever. ---- nayyirah waheed

            (My posts are not intended as advice or professional assessments of any kind.)
            Never forget Excalibur.


            • #8

              UK PHE: `Indian' Variant B.1.617.2 Reclassified As a Variant of Concern (VOC)


              • #9
                UK: Growing Concerns Over The B.1.617.2 Variant's Impact On Reopening Society

                Confirmed cases of VOC-21APR-02by week - Credit PHE

                Due to a time lag in sequencing (approximately 10 to 14 days) and the prioritisation
                of samples of concern, variants cases can be identified weeks after the sample date.
                The numbers represent weekly new cases, not a cumulative total for each week.


                As COVID cases continue to fall across much of the globe, the United States, Japan, the UK, and a number of other European nations have announced plans to relax social distancing requirements and reopen society in the weeks ahead.

                Yesterday we looked at the new CDC Guidance on ditching facemasks When You?ve Been Fully Vaccinated, while many states have already announced they are open for business.

                On Sunday the UK is scheduled to ease lockdown rules (see UK guidance How the rules will change on 17 May), with an eye towards lifting many of their remaining restrictions on June 21st.

                Japan insists - despite its current state of emergency - that they will hold the summer Olympics in August, and the general feeling (at least in many western nations where COVID cases are slowing) is that with the aid of the highly effective COVID vaccine, the worst of the pandemic may be behind us.

                While everyone certainly hopes these reopenings can go as planned, there are growing concerns over what is happening with COVID in South East Asia (primarily India, but also neighboring nations), and lingering concerns over Brazil's ongoing 2nd wave.

                Both, as far as we can tell, are being largely driven by (different) emerging COVID variants; B.1.617.x in India and P.1, P.2, P.3 in Brazil.

                WHO COVID Epidemiological Report As of May 9th

                These variants, while most commonly reported in these two hardest hit nations, are spreading globally and appear biologically `fit' enough to compete with the other major variants around the globe.

                While the Brazilian variant was atop our watch list a couple of months ago, as India's crisis worsens, the B.1.617.2 variant has recently taken center stage.

                Outside of India, the greatest number of B.1.617.x variants have been reported from the UK, and as the graph at the top of this blog post illustrates, it is spreading rapidly. Early reports suggest it is likely more transmissible than the B.1.1.7 (aka `Kent') variant, and there are concerns that the current vaccines may be less effective against it.

                Despite plans to loosen restriction in two days time, and hopefully further reduce them in June, the UK's Prime Minister Boris Johnson gave a statement at a coronavirus press conference last night expressing concerns over the spread of this variant, and how it might affect future plans.
                We believe this variant is more transmissible than the previous one ? in other words it passes more easily from person to person - but we don?t know by how much.

                I am told that if it?s only marginally more transmissible, we can continue more or less as planned.

                But if the virus is significantly more transmissible, we are likely to face some hard choices.

                So ? and this is a balanced decision - I do not believe on present evidence that we need to delay our roadmap, and we will proceed with our plan to move to step 3 in England from Monday.
                But I have to level with you that this could be a serious disruption to our progress and could make it more difficult to move to step 4 in June, and I must again stress we will do whatever it takes to keep the public safe.
                Our surveillance and data gathering is now so advanced, that if there was a danger of the NHS coming under unsustainable pressure, we would see the signs in the data very early on and could react in good time, and that gives us the confidence to continue moving forwards for now.

                But I urge everyone to exercise the greatest caution because the choices we each make in the coming days will have a material effect on the road ahead.

                Early on the UK adopted a policy to delay the 2nd COVID shot for up to 12 weeks (rather than the recommended 4 weeks) in order to get as many people their first dose as quickly as possible.

                Last night, the PM announced - in view of the threat posed by this new variant - plans to speed up 2nd doses for some vulnerable cohorts, based on advice from their JCVI (Joint Committee on Vaccination and Immunisation).

                JCVI advice to mitigate impact of B1.617.2 variant

                The Joint Committee on Vaccination and Immunisation (JCVI) has issued advice to the government on the use of COVID-19 vaccines to mitigate the impact of the B1.617.2 variant of concern.
                From:Public Health England Published 14 May 2021

                The advice is specific to circumstances in the UK at this time.

                Professor Wei Shen Lim, COVID-19 Chair for JCVI, said:

                Due to the rapid rise in cases of the B1.617.2 Variant of Concern and notable transmission in parts of the country, the JCVI advises that every effort is made to promote vaccine uptake in those who remain unvaccinated in priority cohorts 1 to 9 ? these people remain at highest risk of severe outcomes from COVID-19.

                Where vaccine supply allows, particularly in areas where B1.617.2 is a major threat, the second dose of vaccine should be brought forward from 12 to 8 weeks. This is only possible because everyone in the Phase 1 priority groups has already been offered a first dose.

                Alongside these measures, the vaccine programme should continue to be rolled out as quickly as possible. The capacity of vaccination centres should be maximised to enable rapid rollout.

                In a separate statement, Health and Social Care Secretary, Matt Hancock, said:

                While there is no evidence to show this variant has a greater impact on severity of disease or evades the vaccine, the speed of growth is of note and the government is working quickly to ensure the appropriate action is being taken.
                The latest data on the B1.617.2 variant, published by PHE last night, shows the number of cases across the UK has risen from 520 last week to 1,313 cases this week. Most cases are in the North West of England, with some in London.

                It should be noted that the mantra that there is `no evidence' that this variant is more severe or evades the vaccine is based more on a lack of data than anything else. As the following expert reaction, posted on the Science Media Centre website, makes clear - there is a lot about this variant we don't know yet.

                Expert reaction to latest Downing Street Press Conference on the B.1.617.2 variant (?Indian? variant)

                At the coronavirus press conference this afternoon Boris Johnson made a statement on the SARS-CoV-2 variant first identified in India, B.1.617.2.

                Prof Jonathan Ball, Professor of Molecular Virology, University of Nottingham, said:

                ?The main threat to vaccine success and return to normality has been the emergence and spread of variants that are able to escape the protection offered by vaccines. Evidence so far suggests that the vaccines should still be effective against the variant of concern first identified in India, but this is far from clear.

                ?Whilst most vulnerable people have had both doses of vaccine, and therefore will have the highest levels of immunity, there is still a large proportion of the population who have only had a single dose or no dose at all, and it is likely that many of these could become infected and potentially transmit the virus. Whilst the vaccines continue to protect the most vulnerable then this should not be a problem, but there is a potential risk of the virus acquiring more mutations, especially if it continues to spread in a partially immune population. That?s why it makes sense to reduce the interval between vaccine doses and ramp up vaccine coverage in potential hotspots.

                ?Of course, if heightened vaccine programmes can?t control its spread, and hospitalisations start to increase and threaten the NHS, then restrictions are all you have left. We aren?t there yet by any means, but we must keep a very close eye on things to ensure things don?t get out of hand again.

                ?Keeping the lid on the spread of this variant isn?t going to be easy, but hopefully early indicators of continued vaccine effectiveness against this variant, will minimise its impact.?

                Whether B.1.617.x turn out to be a tempest in a teasmade, or something we'll seriously have to contend with in the months ahead, remains to be seen.

                But as long as COVID burns, unchecked, anywhere in the world the virus has the ability - and is granted the opportunity - to remake itself into a more formidable foe.

                Which means, as tempting as it is, we can't afford to declare victory just yet.

                All medical discussions are for educational purposes. I am not a doctor, just a retired paramedic. Nothing I post should be construed as specific medical advice. If you have a medical problem, see your physician.


                • kiwibird
                  kiwibird commented
                  Editing a comment

                  Five residents of a care home in Borsbeek in Antwerp province have been infected with the so-called Indian variants of Covid-19, according to the Flemish Agency for Health and Care (AZG). One of those affected has died.

                  The variant, proper name B.1.617+ or G/452.V3, first appeared in India in October last year and is thought to be more transmissible than previous variants. The effectiveness of existing vaccines is still being studied.
                  All of the home?s residents have been fully vaccinated. ?It is too early to arrive at any conclusions,? said Joris Moonens of the AZG.

                  In three of the cases involved in the new outbreak, the Indian variant has been confirmed, and it is supposed the same goes for the other two. One has since died, and another is in hospital.

                  This is the first time the Indian variant has been found in a care home, according to the VRT. Those infected have been placed in isolation, and the home has suspended all visits for the time being, Moonens said.

                  Report stating care home staff vaccinated with Astrazeneca had tested positive for the B. 1.617.2 strain - no serious cases.


                  In London, it revealed that some had been identified in care homes.

                  In one care home, 15 cases of B.1.617.2 of the variant had been detected and four cases have been hospitalised with non-severe illness - no deaths have been reported.

                • kiwibird
                  kiwibird commented
                  Editing a comment

                  Five residents of a care home in Borsbeek in Antwerp province have been infected with the so-called Indian variants of Covid-19, according to the Flemish Agency for Health and Care (AZG). One of those affected has died.

                  The variant, proper name B.1.617+ or G/452.V3, first appeared in India in October last year and is thought to be more transmissible than previous variants. The effectiveness of existing vaccines is still being studied.
                  All of the home?s residents have been fully vaccinated. ?It is too early to arrive at any conclusions,? said Joris Moonens of the AZG.

                  In three of the cases involved in the new outbreak, the Indian variant has been confirmed, and it is supposed the same goes for the other two. One has since died, and another is in hospital.

                  This is the first time the Indian variant has been found in a care home, according to the VRT. Those infected have been placed in isolation, and the home has suspended all visits for the time being, Moonens said.

                  Report stating care home staff vaccinated with Astrazeneca had tested positive for the B. 1.617.2 strain - no serious cases.


                  In London, it revealed that some had been identified in care homes.

                  In one care home, 15 cases of B.1.617.2 of the variant had been detected and four cases have been hospitalised with non-severe illness - no deaths have been reported.

              • #10
                Reposting this article from the Oklahoma thread because I believe an important piece of news has been neglected to be recognized in Oklahoma. And that is that three of the people in the 17 person cluster had been fully vaccinated with the Moderna vaccine. And two were partially vaccinated. Other than a couple of articles on the internet there as been nothing reported on the local television news.

                Oklahoma - B.1.617.2 Variant Detected

                Yesterday, 03:40 PM
                Health officials identify cluster of 17 recent cases of Indian COVID-19 variant in Oklahoma

                OKLAHOMA CITY ?

                The Oklahoma State Department of Health announced Friday it has identified a cluster of 17 recent cases of the B.1.617.2 variant, commonly referred to as the India variant, in the state.

                Of those, 13 confirmed cases were associated with Cleveland County, according to the OSDH. To date, officials said a total of 18 cases of the B.1.617.2 variant have been identified in the state.

                According to OSDH officials, three of the 17 were fully vaccinated with the Moderna vaccine and two were partially vaccinated at the time of onset. Symptom onsets range from April 16 through April 27.




                • Emily
                  Emily commented
                  Editing a comment
                  Seems good news. Most vaccinated in OK are high risk and this group has not been hospitalized. The vaccine was probably helpful. The group relying on natural immunity is also staying out of the hospital. Everyone in both groups is symptomatic, so they aren't silently spreading the illness.

                • Emily
                  Emily commented
                  Editing a comment
                  Situation might be worse than I thought. CDC is in full cover-up mode.


                • Okieman
                  Okieman commented
                  Editing a comment
                  Hello Emily. It might be worth reviewing the questions I posted (and the discussions that followed) at the top of the FluTrackers thread found here:

                  I do not expect to be told the any government. So, I search for the closest approximation of the truth I am able to find and use critical thinking skills to fill in the gaps. Even then there is mostly gray areas of unknown.

              • #11
                Cases are ballooning in the U.K. COVID-19: More than 2,300 cases of Indian variant now in UK, Matt Hancock says



                • #12
                  My perception from monitoring media from India is that medics were prioritised for vaccines fairly early after they became available. Whilst there ARE reports that many medics have gone off sick with Covid in this latest outbreak, there are not large numbers of reports of them being hospitalised and dying. I am sure we would have heard more about this if it were a large problem, so by deduction, it would suggest that the vaccines are providing protection from serious illness and death, if not infection itself. Obviously not hard data, but for now its all there is to go on.


                  • #13

                    Two vaccine doses needed for strong protection against variant found in India, data show
                    UK government figures suggest single shot less effective against fast-spreading Covid-19 strain
                    John Burn-Murdoch, Anna Gross and Sarah Neville in London 4 hours ago

                    New UK government research suggests two doses of a Covid-19 vaccine are needed to provide strong protection against symptomatic infection from the coronavirus variant first identified in India, according to two people briefed on the preliminary data.

                    Two vaccine doses provided 81 per cent protection against the B.1.617.2 variant found in India, and 87 per cent against the B.1.1.7 strain first identified in Kent in south-east England, according to the Public Health England data that was presented to a meeting of the government?s New and Emerging Respiratory Virus Threats Advisory Group (Nervtag).

                    Two people who attended the Nervtag meeting on Friday said the data showed that one dose offered 33 per cent protection against symptomatic infection from B.1.617.2, and 51 per cent against B.1.1.7...


                    • #14

                      Vaccines highly effective against B.1.617.2 variant after 2 doses

                      New study by PHE shows for the first time that 2 doses of the COVID-19 vaccines are highly effective against the B.1.617.2 variant first identified in India.

                      From:Public Health England
                      Published22 May 2021Last updated22 May 2021 ? See all updates

                      Vaccine effectiveness against symptomatic disease from the B.1.617.2 variant is similar after 2 doses compared to the B.1.1.7 (Kent) variant dominant in the UK, and we expect to see even higher levels of effectiveness against hospitalisation and death.

                      The study found that, for the period from 5 April to 16 May:
                      • the Pfizer-BioNTech vaccine was 88% effective against symptomatic disease from the B.1.617.2 variant 2 weeks after the second dose, compared to 93% effectiveness against the B.1.1.7 variant
                      • 2 doses of the AstraZeneca vaccine were 60% effective against symptomatic disease from the B.1.617.2 variant compared to 66% effectiveness against the B.1.1.7 variant
                      • both vaccines were 33% effective against symptomatic disease from B.1.617.2, 3 weeks after the first dose compared to around 50% effectiveness against the B.1.1.7 variant

                      The analysis included data for all age groups from 5 April to cover the period since the B.1.617.2 variant emerged. It included 1,054 people confirmed as having the B.1.617.2 variant through genomic sequencing, including participants of several ethnicities. Data published on Thursday 20 May for vaccine effectiveness covered the period since December for those aged over 65.

                      The difference in effectiveness between the vaccines after 2 doses may be explained by the fact that rollout of second doses of AstraZeneca was later than for the Pfizer-BioNTech vaccine, and other data on antibody profiles show it takes longer to reach maximum effectiveness with the AstraZeneca vaccine.

                      As with other variants, even higher levels of effectiveness are expected against hospitalisation and death. There are currently insufficient cases and follow-up periods to estimate vaccine effectiveness against severe outcomes from the B.1.617.2 variant. PHE will continue to evaluate this over the coming weeks.

                      Health and Social Care Secretary Matt Hancock said:
                      This new evidence is groundbreaking ? and proves just how valuable our COVID-19 vaccination programme is in protecting the people we love.

                      We can now be confident that over 20 million people ? more than 1 in 3 ? have significant protection against this new variant, and that number is growing by the hundreds of thousands every single day as more and more people get that vital second dose. I want to thank the scientists and clinicians who have been working around the clock to produce this research.

                      It?s clear how important the second dose is to secure the strongest possible protection against COVID-19 and its variants ? and I urge everyone to book in their jab when offered.

                      Dr Mary Ramsay, Head of Immunisation at PHE, said:
                      This study provides reassurance that 2 doses of either vaccine offer high levels of protection against symptomatic disease from the B.1.617.2 variant.

                      We expect the vaccines to be even more effective at preventing hospitalisation and death, so it is vital to get both doses to gain maximum protection against all existing and emerging variants.

                      Minister for COVID-19 Vaccine Deployment Nadhim Zahawi said:
                      Almost every day we get more and more encouraging evidence about the difference our COVID-19 vaccines are making to people?s lives ? with 13,000 lives saved and 39,100 hospitalisations prevented overall.

                      Today?s data is astounding and a true reflection of just how important it is to get both your jabs when offered.

                      I encourage all those offered an appointment to get their jab booked in as soon as possible and take full advantage of the high levels of protection the vaccines bring.

                      Separate PHE analysis indicates that the COVID-19 vaccination programme has so far prevented 13,000 deaths and around 39,100 hospitalisations in older people in England, up to 9 May.

                      Public Health England press office

                      Wellington House
                      133-155 Waterloo Road
                      SE1 8UG


                      Telephone020 7654 8400

                      Out of hours020 8200 4400



                      • sharon sanders
                        sharon sanders commented
                        Editing a comment

                        hat tip Michael Coston for link


                        Evidence of reduced vaccine effectiveness National vaccine effectiveness monitoring shows a reduction in vaccine effectiveness against symptomatic infection after 1 dose of vaccine for B.1.617.2 compared to B.1.1.7 (moderate confidence).

                        Current data suggest this is an absolute reduction of approximately 20% after 1 dose. Vaccine effectiveness is higher and similar between variants after 2 doses with a possible small reduction for B.1.617.2 (low confidence).

                        Although this is observational data subject to some biases, it holds true across several analytic approaches, is consistent with observed outbreaks, and is supported by pseudovirus and live virus neutralisation data. There are no data on whether prevention of transmission is affected.

                        There are insufficient data on vaccine effectiveness against severe disease. Based on neutralisation data, vaccines are expected to remain effective against severe disease.

                        Monitoring continues.

                        Risk assessment for SARS-CoV-2 variant: VOC-21APR-02 (B.1.617.2) (

                    • #15

                      China Disease Control: The transmission capacity of the mutant virus that caused the Guangzhou epidemic was doubled compared to the old strain

                      On the afternoon of June 11, the Joint Prevention and Control Mechanism of the State Council held a press conference in Beijing to introduce the situation of epidemic prevention and control and vaccination. Feng Zijian, a researcher at the Chinese Center for Disease Control and Prevention, said at the press conference that the existing research data shows that the mutant strain that caused the Guangzhou epidemic has a relatively strong transmission capacity. It is twice as powerful as the old strain in the past, and is the first in the United Kingdom. The transmission capacity of the discovered strains has increased by more than 40%.
                      Feng Zijian said that the outbreak in Guangzhou was caused by the B.1.617.2 mutant strain that was first discovered in India. The World Health Organization recently named it the Delta mutant strain, which is the Latin alphabet Alpha, Beta, and Delta. To name it, this strain was named Delta mutant. Alpha mutant is actually the first B.1.1.7 mutant found in the UK. According to the data of the previous foreign research, the research on its transmission ability, cure rate, virulence rate, etc., as well as its immune escape has been continuously updated recently.
                      Feng Zijian introduced that this epidemic has its own characteristics, especially the number of middle-aged and elderly cases, clusters of cases, gatherings, and gatherings. This is also related to the specific lifestyle of Guangdong cities, such as drinking morning tea in venues. The vaccination rate of cases before the onset of infection is relatively low, which puts forward new and higher requirements for the implementation of epidemic response and prevention and control measures.
                      "Guangzhou has recently implemented strict prevention and control strategies and measures. The epidemic prevention and control situation has tended to ease, and it is developing in a very positive direction. The epidemic is in a controllable state." Feng Zijian said, in fact, since China has entered normalized prevention and control , There have been local transmission epidemics in many places in China, but these local epidemics have been found through on-site epidemiology, molecular epidemiology, seroepidemiology and digital epidemiology traceability investigations, and they are all related to overseas imported cases and imports. The related goods indicate that China’s current risk is still imported from abroad, and China is still in the normalized prevention and control stage of "preventing foreign import and preventing internal rebound."
                      Other key points of the conference:
                      Have people with new crown infection in Guangdong vaccinated? Is the vaccine not effective enough? CDC response
                      Can the child get the new crown vaccine? National Health Commission: Organizing experts to study and formulate policies
                      Can people over 60 be vaccinated? Authoritative response from the National Health Commission
                      National Health Commission: 100 new local confirmed cases since June
                      National Health Commission: As of June 10, a total of 84.529 million doses of new crown vaccine have been reported
                      Several people in Qianjiang have weakly positive nucleic acid tests due to contamination during vaccination. China CDC responds